Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04609215

ImmunoBreast - A Phase Ib Study

ImmunoBreast - A Phase Ib Study to Investigate the Safety, Tolerability and Trends of Efficacy of ALECSAT Treatment as an add-on Therapy to Carboplatin and Gemcitabine in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer

Sponsor: CytoVac A/S

Conditions Breast Cancer Metastatic Breast Cancer Triple Negative Breast Cancer

Interventions ALECSAT

Updated 6 times since 2020 Last updated: Apr 19, 2022 Started: Apr 21, 2020 Primary completion: May 21, 2023 Completion: May 21, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Breast Cancer and Metastatic Breast Cancer and is currently ongoing. CytoVac A/S leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2024 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
May 2022 — May 2024 [monthly]

Recruiting PHASE1_PHASE2
Jan 2021 — May 2022 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 1 earlier version

Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Apr 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CytoVac A/S
Henrik Ditzel
National Board of Health, Denmark

Data source: Odense University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Odense, Denmark
• Vejle, Denmark